Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
LEXX

LEXX - Lexaria Bioscience Corp. Stock Price, Fair Value and News

2.74USD-0.02 (-0.72%)Delayed as of 19 Jul 2024, 12:37 pm ET

Market Summary

LEXX
USD2.74-0.02
Delayedas of 19 Jul 2024, 12:37 pm
-0.72%

LEXX Stock Price

View Fullscreen

LEXX RSI Chart

LEXX Valuation

Market Cap

43.6M

Price/Earnings (Trailing)

-14.21

Price/Sales (Trailing)

110.31

EV/EBITDA

-16.44

Price/Free Cashflow

-9.31

LEXX Price/Sales (Trailing)

LEXX Profitability

Operating Margin

93.40%

EBT Margin

-574.26%

Return on Equity

-31.5%

Return on Assets

-30.65%

Free Cashflow Yield

-10.75%

LEXX Fundamentals

LEXX Revenue

Revenue (TTM)

395.6K

Rev. Growth (Yr)

-9.82%

Rev. Growth (Qtr)

-42.07%

LEXX Earnings

Earnings (TTM)

-3.1M

Earnings Growth (Yr)

99.89%

Earnings Growth (Qtr)

99.6%

Breaking Down LEXX Revenue

52 Week Range

0.762.77
(Low)(High)

Last 7 days

-2.1%

Last 30 days

-7.4%

Last 90 days

25%

Trailing 12 Months

252.6%

How does LEXX drawdown profile look like?

LEXX Financial Health

Current Ratio

58.27

LEXX Investor Care

Shares Dilution (1Y)

95.39%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024404.7K395.6K00
2023328.6K322.1K226.2K279.8K
2022489.1K372.2K255.4K339.3K
2021650.3K817.9K722.7K605.9K
2020406.7K250.5K252.6K495.9K
2019501.1K628.6K670.9K626.6K
2018183.5K219.3K289.1K325.8K
201748.5K68.6K64.0K113.9K
201667.7K69.8K86.5K45.8K
201543.7K44.8K45.9K62.6K
2014863.1K394.4K159.1K42.5K
20131.5M1.6M1.3M1.1M
20121.1M978.6K1.1M1.4M
2011555.3K748.2K941.1K1.1M
2010000362.5K

Tracking the Latest Insider Buys and Sells of Lexaria Bioscience Corp.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 14, 2024
carle vanessa
acquired
5,750
1.15
5,000
secretary
Feb 09, 2023
turkel catherine c.
bought
4,266
2.8446
1,500
-
Oct 14, 2022
downey gregory
bought
252
2.09
121
chief financial officer
Oct 14, 2022
downey gregory
acquired
252
2.09
121
chief financial officer
Oct 13, 2022
bunka christopher
bought
34,860
2.1
16,600
chief executive officer
Oct 13, 2022
bunka christopher
acquired
34,860
2.1
16,600
ceo
Oct 12, 2022
bunka christopher
bought
43,537
1.988
21,900
chief executive officer
Oct 12, 2022
bunka christopher
acquired
43,537
1.988
21,900
ceo
May 24, 2022
reese albert l jr
acquired
9,790
1.958
5,000
-

1–10 of 13

Which funds bought or sold LEXX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 17, 2024
Welch Group, LLC
unchanged
-
-20,400
66,720
-%
Jul 16, 2024
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC
added
33.9
956
38,428
-%
Jul 15, 2024
Aspire Private Capital, LLC
unchanged
-
-340
1,112
-%
Jul 09, 2024
MATHER GROUP, LLC.
new
-
363
363
-%
May 16, 2024
Connective Capital Management, LLC
sold off
-100
-75,000
-
-%
May 15, 2024
MORGAN STANLEY
new
-
84,775
84,775
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
new
-
860
860
-%
May 15, 2024
STATE STREET CORP
new
-
142,663
142,663
-%
May 15, 2024
ADAR1 Capital Management, LLC
added
1,537
94,620
96,652
0.02%
May 15, 2024
Invenomic Capital Management LP
reduced
-35.34
802,976
1,717,950
0.09%

1–10 of 39

Are Funds Buying or Selling LEXX?

Are funds buying LEXX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own LEXX
No. of Funds

Unveiling Lexaria Bioscience Corp.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 25, 2024
boos wayne w
4985%
1,020,000
SC 13D/A
Feb 14, 2024
boos wayne w
7078%
480,000
SC 13D/A
Feb 14, 2024
invenomic capital management lp
7.12%
731,981
SC 13G/A
Sep 18, 2023
boos wayne w
6129%
450,000
SC 13D
Feb 10, 2023
invenomic capital management lp
7.95%
473,103
SC 13G/A
Feb 14, 2022
invenomic capital management lp
6.03%
359,113
SC 13G
Feb 14, 2022
l1 capital global opportunities master fund, ltd.
2.6%
159,000
SC 13G/A
Feb 24, 2021
bunka christopher
9.5%
489,455
SC 13D/A

Recent SEC filings of Lexaria Bioscience Corp.

View All Filings
Date Filed Form Type Document
Jul 17, 2024
8-K
Current Report
Jul 12, 2024
10-Q
Quarterly Report
Jun 11, 2024
EFFECT
EFFECT
Jun 11, 2024
424B3
Prospectus Filed
Jun 07, 2024
CORRESP
CORRESP
Jun 07, 2024
UPLOAD
UPLOAD
Jun 03, 2024
S-1
Initial Public Offering
May 15, 2024
4
Insider Trading
May 10, 2024
4
Insider Trading
May 10, 2024
4
Insider Trading

Peers (Alternatives to Lexaria Bioscience Corp.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.5B
6.8B
-8.98% -3.09%
-7.79
6.94
-64.45% -224.75%
29.9B
2.0B
53.85% 15.29%
-90.16
14.95
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
15.8B
2.5B
-0.97% -4.31%
77.02
6.4
13.74% 186.89%
14.7B
3.8B
6.43% 3.96%
19.69
3.9
8.58% 129.81%
MID-CAP
4.9B
107.9M
-6.08% -24.75%
-8.88
48.09
54.84% -28.31%
4.6B
524.1M
-5.24% -6.22%
-11.04
8.79
394.93% 39.61%
3.9B
251.0M
7.93% 10.52%
-13.16
15.54
73.58% -86.73%
3.4B
240.7M
17.18% -20.08%
-7.26
12.77
-1.03% -213.92%
3.0B
813.8M
21.05% -43.59%
-1.7K
3.65
56.43% 98.83%
2.1B
996.6M
8.34% 84.22%
-5.26
2.1
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
11.69% 23.21%
30.33
4.8
60.38% -34.49%
565.8M
881.7K
20.84% 614.44%
-16.76
481.06
-77.61% 33.36%
269.0M
4.2M
21.26% 49.14%
-2.15
64.66
-66.30% 48.24%
18.2M
2.1M
-7.46% -80.82%
-0.79
7.61
-13.45% 69.54%

Lexaria Bioscience Corp. News

Latest updates
StockTitan17 Jul 202402:30 pm
StockTitan16 Jul 202401:20 pm
American Banking and Market News11 Jul 202410:34 am
Marketscreener.com08 Jul 202407:59 pm
TipRanks21 May 202407:00 am

Lexaria Bioscience Corp. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q2
Revenue-42.1%84.0014515115.0093.0020.0098.0011110031.0031.0031.0020419229612636.0038.0052.00124193
Gross Profit-42.1%84.00145146-3.4380.0017.0082.0070.0081.0024.008.0011.0014416123113416.00-20.562.0011057.00
Operating Expenses124.7%1,8278131,2861,1072,4641,3411,7778182,4991,4732,0121,3132,7111,2669449161,4261,0419791,2261,245
  S&GA Expenses-100.0%-5677116068236459484621,7471,1971,5538742,2561,0907523,78555.0061.0074.0090.0082.00
  R&D Expenses133.2%5732465745001,64169682935675227645944045417619268.0025.00187107162231
EBITDA Margin-1.3%-5.34*-5.27*-7.59*-9.40*-6.75*-6.61*-6.40*-8.49*-5.82*-4.42*-3.56*-2.99*---------
Interest Expenses100.0%--1*--15.0015.00---------------
Income Taxes--------5.00---13.00--3.003.0010.002.00-957*-27.79-
EBT Margin-2.3%-5.74*-5.61*-8.12*-10.04*-7.05*-6.91*-6.70*-8.89*-6.10*-4.64*-3.75*-3.14*---------
Net Income99.6%-2.62-649-1,179-1,239-2,371-1,298-1,755-1,467-2,382-1,425-1,993-1,178-2,566404-696-714-1,390-950-907-37.73-16.13
Net Income Margin42.2%-7.76*-13.44*-21.76*-29.46*-21.40*-21.01*-20.73*-28.46*-10.84*-8.25*-6.66*-5.59*---------
Free Cashflow-104.3%-1,266-619-1,181-1,621-1,785-1,241-1,265-1,176-1,265-1,277-1,208-1,112---------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q2
Assets57.7%10,0186,3523,6273,0845,2404,8556,2137,8349,13811,41511,74613,26710,54812,1722,1742,8283,3201,9862,7462,6753,457
  Current Assets67.9%9,0935,4172,6942,1514,2354,0045,3596,9788,29110,57210,90112,4439,68610,9461,3081,9262,5281,1801,9111,8192,608
    Cash Equivalents79.8%8,4594,7051,9541,3523,1643,2724,5335,8137,0518,3599,68210,9188,1099,3475251,2942,0347401,3331,2851,996
  Inventory------8.0010.0038.0040.0032.0027.0030.0052.00137126117133124134127188
  Net PPE-3.1%219226234254277301311316343--368-423452483511538565591607
Liabilities32.9%2712042544041,19822328220122519527720328147035334612063.00130185132
  Current Liabilities91.0%15682.001252681,05622328219420716623815322139924222691.0063.00130185132
Shareholder's Equity49.5%9,7476,5213,3733,0444,3954,6325,9327,6328,91311,22011,46913,06410,26611,7031,8212,4823,2011,9232,6152,4913,325
  Retained Earnings-3.7%-49,373-47,592-46,942-45,763-44,524-42,152-40,854-39,098-37,631-35,248-33,822-31,829--28,094-28,498-27,802-27,087-25,725-24,775-23,868-22,789
  Additional Paid-In Capital9.9%59,50354,12150,67148,79948,91247,12147,11047,04146,80946,69745,49845,08940,99039,86030,37330,32430,18427,52527,22126,17225,891
Shares Outstanding27.6%15,81012,38810,3128,0928,0925,9515,9515,9515,9515,9515,7275,7275,1043,524-------
Minority Interest-0.7%-375-372-369-364-354-342-329-316-270-235-212-202-77.51-67.96-57.04-42.9414.0043.0090.00108145
Float------16.20*---21,000---27,000---21,566---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q2
Cashflow From Operations-104.3%-1,266-619-1,181-1,621-1,785-1,228-1,245-1,176-1,259-1,277-1,166-1,112-1,156-911-809-639-670-753-555-736-1,101
  Share Based Compensation-342-54.0010.0081.0011.0069.00233111-409-34417.0049.00-683294162119443
Cashflow From Investing61.4%-22.00-56.99-40.03-68.44-33.65-32.68-34.84-50.04-37.96-34.42-58.21-2*-70.73270-5.77-13.64-7.49-1*-5.71-33.09-1,239
Cashflow From Financing46.1%5,0433,4531,819-1211,711---11.20-11.20-11.20-10.994,004-10.999,435-8.77-89.151,91612070759.001,243
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

LEXX Income Statement

2024-05-31
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
3 Months Ended9 Months Ended
May 31, 2024
May 31, 2023
May 31, 2024
May 31, 2023
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)    
Revenue$ 84,000$ 77,707$ 380,278$ 195,467
Cost of goods sold012,7474,82231,500
Gross profit84,00064,960375,456163,967
Operating expenses    
Research and development573,0891,640,6481,393,3593,166,315
General and administrative1,253,830825,1772,532,1632,417,561
Total operating expenses1,826,9192,465,8253,925,5225,583,876
Loss from operations(1,742,919)(2,400,865)(3,550,066)(5,419,909)
Other income (loss)    
Interest income015,4437,31834,174
Unrealized gain (loss) on marketable securities(41,393)1,856(79,335)(77,775)
Total other income (loss)(41,393)17,299(72,017)(43,601)
Net loss(1,784,312)(2,383,566)(3,622,083)(5,463,510)
Less: Net loss attributable to non-controlling interest(2,619)(12,061)(11,528)(37,930)
Net loss attributable to Lexaria shareholders(1,781,693)(2,371,505)(3,610,555)(5,425,580)
Other comprehensive income    
Foreign currency translation adjustment(1,240)0(21,866)0
Total comprehensive loss$ (1,782,933)$ (2,371,505)$ (3,632,421)$ (5,425,580)
Basic and diluted loss per share$ (0.13)$ (0.37)$ (0.32)$ (0.89)
Weighted average number of common shares outstanding    
- Basic and diluted13,855,2026,440,99811,274,8456,116,126

LEXX Balance Sheet

2024-05-31
CONSOLIDATED BALANCE SHEETS - USD ($)
May 31, 2024
Aug. 31, 2023
Current  
Cash$ 8,459,081$ 1,352,102
Marketable securities46,307125,642
Accounts receivable208,445126,686
Prepaid expenses and other current assets379,546546,783
Total Current Assets9,093,3792,151,213
Non-current assets, net  
Long-term receivables63,57548,559
Right of use assets143,316167,446
Intellectual property, net498,878462,625
Property & equipment, net219,289254,143
Total Non-current Assets925,058932,773
TOTAL ASSETS10,018,4373,083,986
Current Liabilities  
Accounts payable and accrued liabilities128,788239,941
Lease liability, current27,26027,794
Total Current Liabilities156,048267,735
Lease liabilities - non-current115,327136,173
TOTAL LIABILITIES271,375403,908
Stockholders' Equity  
Share Capital Authorized: 220,000,000 common voting shares with a par value of $0.001 per share Common shares issued and outstanding: 15,810,205 and 8,091,650 at May 31, 2024, and August 31, 2023, respectively.15,8108,091
Additional paid-in capital59,502,66848,799,454
Accumulated deficit(49,373,982)(45,763,427)
Accumulated other comprehensive loss(21,866)0
Equity attributable to shareholders of Lexaria10,122,6303,044,118
Non-controlling interest(375,568)(364,040)
Total Stockholders' Equity9,747,0622,680,078
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$ 10,018,437$ 3,083,986
LEXX
Lexaria Bioscience Corp. operates as a biotechnology company. The company develops and out-licenses its DehydraTECH combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and various cannabinoids. The company's DehydraTECH technology evaluates for a variety of therapeutic indications, including hypertension, heart disease, dementia, and diabetes. It is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is based in Kelowna, Canada.
 CEO
 WEBSITEhttps://lexariabioscience.com
 INDUSTRYBiotechnology
 EMPLOYEES7

Lexaria Bioscience Corp. Frequently Asked Questions


What is the ticker symbol for Lexaria Bioscience Corp.? What does LEXX stand for in stocks?

LEXX is the stock ticker symbol of Lexaria Bioscience Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lexaria Bioscience Corp. (LEXX)?

As of Thu Jul 18 2024, market cap of Lexaria Bioscience Corp. is 43.64 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LEXX stock?

You can check LEXX's fair value in chart for subscribers.

What is the fair value of LEXX stock?

You can check LEXX's fair value in chart for subscribers. The fair value of Lexaria Bioscience Corp. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Lexaria Bioscience Corp. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LEXX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Lexaria Bioscience Corp. a good stock to buy?

The fair value guage provides a quick view whether LEXX is over valued or under valued. Whether Lexaria Bioscience Corp. is cheap or expensive depends on the assumptions which impact Lexaria Bioscience Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LEXX.

What is Lexaria Bioscience Corp.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 18 2024, LEXX's PE ratio (Price to Earnings) is -14.21 and Price to Sales (PS) ratio is 110.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LEXX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Lexaria Bioscience Corp.'s stock?

In the past 10 years, Lexaria Bioscience Corp. has provided -0.111 (multiply by 100 for percentage) rate of return.